Market capitalization | JPY819.64b |
Enterprise Value | JPY805.81b |
P/E (TTM) P/E ratio | 8.67 |
EV/FCF (TTM) EV/FCF | 7.72 |
EV/Sales (TTM) EV/Sales | 1.66 |
P/S ratio (TTM) P/S ratio | 1.69 |
P/B ratio (TTM) P/B ratio | 1.05 |
Dividend yield | 4.58% |
Last dividend (FY25) | JPY80.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
11 Analysts have issued a Ono Pharmaceutical forecast:
11 Analysts have issued a Ono Pharmaceutical forecast:
Sep '24 |
+/-
%
|
||
Revenue | 484,299 484,299 |
1%
1%
|
|
Gross Profit | 365,061 365,061 |
2%
2%
|
|
EBITDA | 140,405 140,405 |
27%
27%
|
EBIT (Operating Income) EBIT | 122,355 122,355 |
30%
30%
|
Net Profit | 95,140 95,140 |
24%
24%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Gyo Sagara |
Employees | 3,853 |
Founded | 1947 |
Website | www.ono.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.